Antithrombotic therapy for patients with STEMI undergoing primary PCI

Nature Reviews Cardiology

Volumn 14, Issue 6, 2017, Pages 361-379

  Franchi, Francesco ^a   Rollini, Fabiana ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BIVALIRUDIN; CANGRELOR; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PRASUGREL; RIVAROXABAN; TICAGRELOR; TIROFIBAN; VORAPAXAR; FIBRINOLYTIC AGENT;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL (TOPIC); DRUG CHOICE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LOADING DRUG DOSE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; CLASSIFICATION; PROCEDURES; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINES AS TOPIC; ST ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

EID: 85013679455     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2017.18     Document Type: Review

References (152)

1. O'Gara, P. T. et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 61, e78-e140 (2013).
2. Levine, G. N. et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J. Am. Coll. Cardiol. 58, e44-e122 (2011).
3. Steg, P. G. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 33, 2569-2619 (2012).
4. Windecker, S. et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 35, 2541-2619 (2014).
5. Falk, E., Nakano, M., Bentzon, J. F., Finn, A. V. & Virmani, R. Update on acute coronary syndromes: the pathologists' view. Eur. Heart J. 34, 719-728 (2013).
6. Libby, P. Mechanisms of acute coronary syndromes and their implications for therapy. N. Engl. J. Med. 368, 2004-2013 (2013).
7. Davì, G. & Patrono, C. Platelet activation and atherothrombosis. N. Engl. J. Med. 357, 2482-2494 (2007).
8. Angiolillo, D. J., Ueno, M. & Goto, S. Basic principles of platelet biology and clinical implications. Circ. J. 74, 597-607 (2010).
9. Franchi, F. & Angiolillo, D. J. Novel antiplatelet agents in acute coronary syndrome. Nat. Rev. Cardiol. 12, 30-47 (2015).
10. Brass, L. F. Thrombin and platelet activation. Chest 124, 18S-25S (2003).
11. Brummel, K. E., Paradis, S. G., Butenas, S. & Mann, K. G. Thrombin functions during tissue factor-induced blood coagulation. Blood 100, 148-152 (2002).
12. Coughlin, S. R. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost. 3, 1800-1814 (2005).
13. Angiolillo, D. J., Capodanno, D. & Goto, S. Platelet thrombin receptor antagonism and atherothrombosis. Eur. Heart J. 31, 17-28 (2010).
14. Yusuf, S. et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295, 1519-1530 (2006).
15. Garcia, D. A., Baglin, T. P., Weitz, J. I. & Samama, M. M. Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141, e24S-e43S (2012).
16. Salter, B. S. et al. Heparin-induced thrombocytopenia: A comprehensive clinical review. J. Am. Coll. Cardiol. 67, 2519-2532 (2016).
17. Boneu, B. et al. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit. Semin. Thromb. Hemost 14, 18-27 (1988).
18. Palm, M. & Mattsson, C. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb. Res. 40, 129-133 (1985).
19. Montalescot, G. et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet 378, 693-703 (2011).
20. Arsenault, K. A. et al. Direct thrombin inhibitors in cardiovascular disease. Nat. Rev. Cardiol. 9, 402-414 (2012).
21. Kastrati, A. et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N. Engl. J. Med. 365, 1980-1989 (2011).
22. Stone, G. W. et al. Bivalirudin for patients with acute coronary syndromes. N. Engl. J. Med. 355, 2203-2216 (2006).
23. Stone, G. W. et al. Bivalirudin during primary PCI in acute myocardial infarction. N. Engl. J. Med. 358, 2218-2230 (2008).
24. Mehran, R. et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 374, 1149-1159 (2009).
25. Stone, G. W. et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 377, 2193-2204 (2011).
26. Dangas, G. D. et al. Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis. J. Am. Coll. Cardiol. 57, 2309-2316 (2011).
27. Dangas, G. D. et al. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation 123, 1745-1756 (2011).
28. Koutouzis, M. et al. Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: A report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Heart 97, 1484-1488 (2011).
29. Steg, P. G. et al. Bivalirudin started during emergency transport for primary PCI. N. Engl. J. Med. 369, 2207-2217 (2013).
30. Clemmensen, P. et al. Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography). JACC Cardiovasc. Interv. 8, 214-220 (2015).
31. Zeymer, U. et al. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: A pre-specified analysis from the EUROMAX trial. Eur. Heart J. 35, 2460-2467 (2014).
32. Stone, G. W. et al. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials. J. Am. Coll. Cardiol. 65, 27-38 (2015).
33. Shahzad, A. et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): An open-label, single centre, randomised controlled trial. Lancet 384, 1849-1858 (2014).
34. Han, Y. et al. Bivalirudin versus heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA 313, 1336-1346 (2015).
35. Schulz, S. et al. Prasugrel plus bivalirudin versus clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. Eur. Heart J. 35, 2285-2294 (2014).
36. Valgimigli, M. et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. N. Engl. J. Med. 373, 997-1009 (2015).
37. Leonardi, S. et al. Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. BMJ 354, i4935 (2016).
38. Capodanno, D. et al. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials. Eur. Heart J. Acute Cardiovasc. Care 5, 253-262 (2016).
39. Shah, R., Rogers, K. C., Matin, K., Askari, R. & Rao, S. V. An updated comprehensive meta-analysis of bivalirudin versus heparin use in primary percutaneous coronary intervention. Am. Heart J. 171, 14-24 (2016).
40. Muñiz-Lozano, A., Rollini, F., Franchi, F. & Angiolillo, D. J. Update on platelet glycoprotein IIb/ IIIa inhibitors: recommendations for clinical practice. Ther. Adv. Cardiovasc. Dis. 7, 197-213 (2013).
41. Stone, G. W. et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N. Engl. J. Med. 346, 957-966 (2002).
42. Mehilli, J. et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: A randomized double-blind trial. Circulation 119, 1933-1940 (2009).
43. Antoniucci, D. et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J. Am. Coll. Cardiol. 42, 1879-1885 (2003).
44. Van't Hof, A. W. et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): A multicentre, double-blind, randomised controlled trial. Lancet 372, 537-546 (2008).
45. Zeymer, U. et al. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial. J. Am. Coll. Cardiol. 56, 463-469 (2010).
46. Thiele, H. et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 118, 49-57 (2008).
47. Stone, G. W. et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 307, 1817-1826 (2012).
48. Valgimigli, M. et al. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc. Interv. 5, 268-277 (2012).
49. Thiele, H. et al. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: A randomised trial. Lancet 379, 923-931 (2012).
50. De Luca, G. et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis. J. Thromb. Haemost. 9, 2361-2370 (2011).
51. Gershlick, A. H., Banning, A. P., Myat, A., Verheugt, F. W. & Gersh, B. J. Reperfusion therapy for STEMI: is there still a role for thrombolysis in the era of primary percutaneous coronary intervention Lancet 382, 624-632 (2013).
52. Herrmann, H. C. et al. Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. JACC Cardiovasc. Interv. 2, 917-924 (2009).
53. Franchi, F., Rollini, F., Muñiz-Lozano, A., Cho, J. R. & Angiolillo, D. J. Cangrelor: A review on pharmacology and clinical trial development. Expert Rev. Cardiovasc. Ther. 11, 1279-1291 (2013).
54. Franchi, F., Rollini, F., Park, Y. & Angiolillo, D. J. A safety evaluation of cangrelor in patients undergoing PCI. Expert. Opin. Drug Saf. 15, 275-285 (2016).
55. Bhatt, D. L. et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N. Engl. J. Med. 368, 1303-1313 (2013).
56. Généreux, P. et al. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J. Am. Coll. Cardiol. 63, 619-629 (2014).
57. White, H. D. et al. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (a clinical trial comparing cangrelor to clopidogrel standard therapy in subjects who require percutaneous coronary intervention [PCI]). JACC Cardiovasc. Interv. 8, 424-433 (2015).
58. Vaduganathan, M. et al. Evaluation of ischemic and bleeding risks associated with 2 parenteral antiplatelet strategies comparing cangrelor with glycoprotein IIb/IIIa inhibitors: An exploratory analysis from the CHAMPION trials. JAMA Cardiol. http:// dx.doi.org/10.1001/jamacardio.2016.4556 (2016).
59. US Food and Drug Administration. Highlights of prescribing information (cangrelor). FDA www.accessdata.fda.gov/drugsatfda-docs/ label/2015/204958lbl.pdf (2016).
60. European Medicines Agency. Summary of product characteristics (cangrelor). EMA www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product- Information/human/003773/WC500188098.pdf (2016).
61. Roffi, M. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 37, 267-315 (2016).
62. Angiolillo, D. J. et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J. Thromb. Thrombolysis 34, 44-55 (2012).
63. Rollini, F., Franchi, F. & Angiolillo, D. J. Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat. Rev. Cardiol. 13, 11-27 (2016).
64. Steinhubl, S. R. et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb. Res. 121, 527-534 (2008).
65. Dovlatova, N. L., Jakubowski, J. A., Sugidachi, A. & Heptinstall, S. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J. Thromb. Haemost. 6, 1153-1159 (2008).
66. Rollini, F. et al. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients. JACC Cardiovasc. Interv. 7, 426-434 (2014).
67. Schneider, D. J., Agarwal, Z., Seecheran, N. & Gogo, P. Pharmacodynamic effects when clopidogrel is given before cangrelor discontinuation. J. Interv. Cardiol. 28, 415-419 (2015).
68. Schneider, D. J., Seecheran, N., Raza, S. S., Keating, F. K. & Gogo, P. Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron. Artery Dis. 26, 42-48 (2015).
69. Schneider, D. J., Agarwal, Z., Seecheran, N., Keating, F. K. & Gogo, P. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc. Interv. 7, 435-442 (2014).
70. Patrono, C., García Rodríguez, L. A., Landolfi, R. & Baigent, C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 353, 2373-2383 (2005).
71. Capodanno, D. & Angiolillo, D. J. Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus. Circulation 134, 1579-1594 (2016).
72. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2, 349-360 (1988).
73. Campbell, C. L., Smyth, S., Montalescot, G. & Steinhubl, S. R. Aspirin dose for the prevention of cardiovascular disease: A systematic review. JAMA 297, 2018-2024 (2007).
74. Mehta, S. R. et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N. Engl. J. Med. 363, 930-942 (2010).
75. Storey, R. F., Newby, L. J. & Heptinstall, S. Effects of P2Y 1 and P2Y 12 receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 12, 443-447 (2001).
76. Altman, R., Scazziota, A., Rouvier, J. & Gonzalez, C. Effects of ticlopidine or ticlopidine plus aspirin on platelet aggregation and ATP release in normal volunteers: why aspirin improves ticlopidine antiplatelet activity. Clin. Appl. Thromb. Hemost. 5, 243-246 (1999).
77. Schömig, A. et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med. 334, 1084-1089 (1996).
78. Bertrand, M. E. et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 98, 1597-1603 (1998).
79. Leon, M. B. et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N. Engl. J. Med. 339, 1665-1671 (1998).
80. Urban, P. et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 98, 2126-2132 (1998).
81. Yusuf, S. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494-502 (2001).
82. Steinhubl, S. R. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 288, 2411-2420 (2002).
83. Sabatine, M. S. et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 352, 1179-1189 (2005).
84. Chen, Z. M. et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366, 1607-1621 (2005).
85. Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007).
86. Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045-1057 (2009).
87. Love, B., Biller, J. & Gent, M. Adverse haematological effects of ticlopidine: prevention, recognition and management. Drug Saf. 19, 89-98 (1998).
88. Bhatt, D. L. et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J. Am. Coll. Cardiol. 39, 9-14 (2002).
89. Fan, W., Plent, S., Prats, J. & Deliargyris, E. N. Trends in P2Y12 inhibitor use in patients referred for invasive evaluation of coronary artery disease in contemporary US practice. Am. J. Cardiol. 117, 1439-1443 (2016).
90. Sherwood, M. W. et al. Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. J. Am. Heart Assoc. 3, e000849 (2014).
91. Bueno, H. et al. Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns. Eur. Heart J. Acute Cardiovasc. Care 5, 3-12 (2016).
92. Angiolillo, D. J. et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. 49, 1505-1516 (2007).
93. Tantry, U. S. et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J. Am. Coll. Cardiol. 62, 2261-2273 (2013).
94. Sugidachi, A. et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J. Thromb. Haemost. 5, 1545-1551 (2007).
95. Wiviott, S. D. et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation thrombolysis in myocardial infarction 44 trial. Circulation 116, 2923-2932 (2007).
96. Montalescot, G. et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373, 723-731 (2009).
97. Udell, J. A. et al. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: A TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38). JACC Cardiovasc. Interv. 7, 604-612 (2014).
98. Gurbel, P. A. et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120, 2577-2585 (2009).
99. Cattaneo, M., Schulz, R. & Nylander, S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J. Am. Coll. Cardiol. 63, 2503-2509 (2014).
100. Bonaca, M. P. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 372, 1791-1800 (2015).
101. Bonaca, M. P. et al. Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events: A secondary analysis of the PEGASUS-TIMI 54 trial. JAMA Cardiol. 1, 425-432 (2016).
102. Steg, P. G. et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 122, 2131-2141 (2010).
103. Velders, M. A. et al. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart 102, 617-625 (2016).
104. Wisler, J. W. & Becker, R. C. Oral factor Xa inhibitors for the long-term management of ACS. Nat. Rev. Cardiol. 9, 392-401 (2012).
105. Brummel-Ziedins, K. et al. Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition. J. Thromb. Haemost. 6, 104-110 (2008).
106. Franchi, F., Rollini, F., Park, Y. & Angiolillo, D. J. Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development. Future Cardiol. 11, 547-564 (2015).
107. Tricoci, P. et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N. Engl. J. Med. 366, 20-33 (2012).
108. Morrow, D. A. et al. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366, 1404-1413 (2012).
109. Morrow, D. A. et al. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke 44, 691-698 (2013).
110. Scirica, B. M. et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: A prespecified subgroup analysis of the TRA 2P-TIMI 50 trial. Lancet 380, 1317-1324 (2012).
111. US Food and Drug Administration. Highlights of prescribing information (vorapaxar). FDA www.accessdata.fda.gov/drugsatfda-docs/ label/2014/204886s000lbl.pdf (2016).
112. European Medicines Agency. Summary of product characteristics (vorapaxar). EMA www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product- Information/human/002814/WC500183329.pdf (2016).
113. Oldgren, J. et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: A systematic review and meta-analysis. Eur. Heart J. 34, 1670-1680 (2013).
114. Mega, J. L. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 366, 9-19 (2012).
115. Mega, J. L. et al. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction-51). J. Am. Coll. Cardiol. 61, 1853-1859 (2013).
116. Povsic, T. J. et al. A randomized trial to compare the safety of rivaroxaban versus aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: the design of the GEMINI-ACS-1 phase II study. Am. Heart J. 174, 120-128 (2016).
117. European Medicines Agency. Summary of product characteristics (rivaroxaban). EMA www.ema.europa. eu/docs/en-GB/document-library/EPAR-Product- Information/human/000944/WC500057108.pdf (2016).
118. Gibson, C. M. et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N. Engl. J. Med. 375, 1131-1141 (2016).
119. Angiolillo, D. J. et al. Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: A North American perspective - 2016 update. Circ. Cardiovasc. Interv. 9, e004395 (2016).
120. Rollini, F. & Franchi, F. The conundrum of platelet P2Y12 inhibition in ST-segment elevation myocardial infarction. Circ. J. 80, 2429-2431 (2016).
121. Alexopoulos, D. et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ. Cardiovasc. Interv. 5, 797-804 (2012).
122. Parodi, G. et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J. Am. Coll. Cardiol. 61, 1601-1606 (2013).
123. Franchi, F. et al. Impact of escalating loading dose regimens of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of a prospective randomized pharmacokinetic and pharmacodynamic investigation. JACC Cardiovasc. Interv. 8, 1457-1467 (2015).
124. Alexopoulos, D. et al. Double versus standard loading dose of ticagrelor: onset of antiplatelet action in patients with STEMI undergoing primary PCI. J. Am. Coll. Cardiol. 62, 940-941 (2013).
125. Alexopoulos, D. et al. Onset of antiplatelet action with high (100 mg) versus standard (60 mg) loading dose of prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: pharmacodynamic study. Circ. Cardiovasc. Interv. 7, 233-239 (2014).
126. Parodi, G. et al. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study. Am. Heart J. 167, 909-914 (2014).
127. Rollini, F. et al. Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study. J. Am. Coll. Cardiol. 67, 1994-2004 (2016).
128. Parodi, G. et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J. Am. Coll. Cardiol. 65, 511-512 (2015).
129. Stone, G. W. et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): A prospective multicenter registry study. Lancet 382, 614-623 (2013).
130. Capodanno, D. & Angiolillo, D. J. Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines. Circ. Cardiovasc. Interv. 8, e002301 (2015).
131. Bellemain-Appaix, A. et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis. JAMA 308, 2507-2516 (2012).
132. Montalescot, G. et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N. Engl. J. Med. 371, 1016-1027 (2014).
133. Silvain, J. et al. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study. Thromb. Haemost. 116, 369-378 (2016).
134. Montalescot, G. et al. Effect of pre-hospital ticagrelor during the first 24 h after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: the ATLANTIC-H24 analysis. JACC Cardiovasc. Interv. 9, 646-656 (2016).
135. Parodi, G. et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ. Cardiovasc. Interv. 8, e001593 (2014).
136. Silvain, J. et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ 344, e553 (2012).
137. Alexander, K. P. et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294, 3108-3116 (2005).
138. Angiolillo, D. J. et al. Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. J. Thromb. Thrombolysis 40, 317-322 (2015).
139. Rollini, F. et al. A head-to-head pharmacodynamic comparison of prasugrel versus ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. Eur. Heart J. 37, 2722-2730 (2016).
140. Franchi, F. et al. Pharmacodynamic comparison of prasugrel versus ticagrelor in patients with type 2 diabetes mellitus and coronary artery disease: the OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 study. Circulation 134, 780-792 (2016).
141. Rafique, A. M. et al. Optimal P2Y12 inhibitor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A network meta-analysis. JACC Cardiovasc. Interv. 9, 1036-1046 (2016).
142. Cuisset, T., Capodanno, D. & Wijns, W. Optimal P2Y12 inhibitor for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: network meta-analysis in the data-free zone: do you believe in magic JACC Cardiovasc. Interv. 9, 1047-1050 (2016).
143. Motovska, Z. et al. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 study. Circulation 134, 1603-1612 (2016).
144. Schulz, S. et al. Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy - design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial. J. Cardiovasc. Transl. Res. 7, 91-100 (2014).
145. Gross, L. & Sibbing, D. Current role of platelet function testing in percutaneous coronary intervention and coronary artery bypass grafting. Interv. Cardiol. Clin. 6, 151-166 (2017).
146. Franchi, F. et al. Platelet function testing in contemporary clinical and interventional practice. Curr. Treat. Options Cardiovasc. Med. 16, 300 (2014).
147. Bergmeijer, T. O. et al. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients - rationale and design of the patient outcome after primary PCI (POPular) genetics study. Am. Heart J. 168, 16-22.e1 (2014).
148. Mixon, T. A. et al. Retrospective description and analysis of consecutive catheterization laboratory ST-segment elevation myocardial infarction activations with proposal, rationale, and use of a new classification scheme. Circ. Cardiovasc. Qual. Outcomes 5, 62-69 (2012).
149. McDaniel, M. Pre-hospital ticagrelor in ST-segment elevation myocardial infarction Probably not. JACC Cardiovasc. Interv. 9, 657-659 (2016).
150. Park, Y., Franchi, F., Rollini, F. & Angiolillo, D. J. Dual antiplatelet therapy after coronary stenting. Expert Opin. Pharmacother. 17, 1775-1787 (2016).
151. Levine, G. N. et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 68, 1082-1115 (2016).
152. Sardella, G., Calcagno, S. & Mancone, M. Different prasugrel administration in STEMI patients: go faster and no fear to crush! J. Am. Coll. Cardiol. 67, 2005-2007 (2016).